Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia-reperfusion injury

被引:121
作者
Birnbaum, Y [1 ]
Ye, YM [1 ]
Rosanio, S [1 ]
Tavackoli, S [1 ]
Hu, ZY [1 ]
Schwarz, ER [1 ]
Uretsky, BF [1 ]
机构
[1] Univ Texas, Med Branch, Dept Internal Med, Div Cardiol, Galveston, TX 77555 USA
关键词
cyclooxygenase; infarction; phospholipases; prostaglandins; statins;
D O I
10.1016/j.cardiores.2004.10.018
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: Statins attenuate myocardial ischemic injury by activating nitric oxide synthase (NOS). It is unknown whether cyclooxygenase-2 (COX2), which mediates late ischemic preconditioning, also mediates statins-induced cardioprotection. We investigated the involvement of the prostaglandins and NOS in the cardioprotective effect of atorvastatin (ATV) in the rat. Methods: Sprague-Dawley rats were randomized to a 3-day oral treatment with ATV 10 mg/kg, valdecoxib, a selective COX2 inhibitor (VAL) 3 mg/kg, ATV+VAL or water alone. Rats underwent 30-min myocardial ischemia followed by 4-h reperfusion. Results: Infarct size was smaller in the ATV group (31.3 +/- 1.9%) than controls (44.5 +/- 3.1%; p=0.011) and VAL (44.5 +/- 3.1%; p=0.008). VAL attenuated the protective effect of ATV when administered together (40.2 +/- 2.5%). ATV pretreatment increased myocardial content of 6-keto-PGF(1alpha) (69.5 +/- 1.5 pg/mg) and PGE(2) (57.9 +/- 0.6 pg/mg) compared with controls (16.2 +/- 0.2 and 42.1 +/- 2.0 pg/mg, respectively) and ATV+VAL (15.8 +/- 0.3 and 39.9 +/- 1.9 pg/mg, respectively). ATV increased myocardial content of cytosolic phospholipase A(2) (cPLA(2)) (174.8 +/- 0.5%) COX2 (446.2 +/- 0.9%), PGI(2) synthase (201.8 +/- 1.1%) and PGE2 synthase (122 +/- 0.7%), whereas ATV+VAL did not (123.0 +/- 7.9%, 93.8 +/- 8.5%, 103.0 +/- 1.6% and 99.0 +/- 0%, respectively). ATV did not change the myocardial content of eNOS and nNOS, but increased the concentration of phosphorylated eNOS (231.8 +/- 2.4%) and iNOS (154.5 +/- 1.2%). This effect was not blocked by coadministration of VAL (231.5 +/- 3.0% and 154.5 +/- 1.8%, respectively). Conclusions: Our results suggest that the prostaglandins are essential for mediating the myocardial protective effects of ATV and their production is downstream to eNOS phosphorylation and iNOS. (C) 2004 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:345 / 355
页数:11
相关论文
共 56 条
[1]   Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice [J].
Amin-Hanjani, S ;
Stagliano, NE ;
Yamada, M ;
Huang, PL ;
Liao, JK ;
Moskowitz, MA .
STROKE, 2001, 32 (04) :980-985
[2]   Nitric oxide as a mediator of delayed pharmacological (A1 receptor triggered) preconditioning;: is eNOS masquerading as iNOS? [J].
Bell, RM ;
Smith, CCT ;
Yellon, DM .
CARDIOVASCULAR RESEARCH, 2002, 53 (02) :405-413
[3]   Reduction of infarct size by short-term pretreatment with atorvastatin [J].
Birnbaum, Y ;
Ashitkov, T ;
Uretsky, BF ;
Ballinger, S ;
Motamedi, M .
CARDIOVASCULAR DRUGS AND THERAPY, 2003, 17 (01) :25-30
[4]   Cerivastatin inhibits proliferation of interleukin-1β-induced rat mesangial cells by enhanced formation of nitric oxide [J].
Blume, C ;
Sabuda-Widemann, D ;
Pfeilschifter, J ;
Plum, J ;
Schrör, K ;
Grabensee, B ;
Beck, KF .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2004, 485 (1-3) :1-10
[5]   Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning [J].
Bolli, R ;
Shinmura, K ;
Tang, XL ;
Kodani, E ;
Xuan, YT ;
Guo, YR ;
Dawn, B .
CARDIOVASCULAR RESEARCH, 2002, 55 (03) :506-519
[6]   Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention [J].
Chan, AW ;
Bhatt, DL ;
Chew, DP ;
Quinn, MJ ;
Moliterno, DJ ;
Topol, EJ ;
Ellis, SG .
CIRCULATION, 2002, 105 (06) :691-696
[7]   Nitric oxide induces expression of cyclooxygenase-2 in mouse skin through activation of NF-κB [J].
Chun, KS ;
Cha, HH ;
Shin, JW ;
Na, HK ;
Park, KK ;
Chung, WY ;
Surh, YJ .
CARCINOGENESIS, 2004, 25 (03) :445-454
[8]   Suppression of the functionally coupled cyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans [J].
Cipollone, F ;
Fazia, M ;
Iezzi, A ;
Zucchelli, M ;
Pini, B ;
De Cesare, D ;
Ucchino, S ;
Spigonardo, F ;
Bajocchi, G ;
Bei, R ;
Muraro, R ;
Artese, L ;
Piattelli, A ;
Chiarelli, F ;
Cuccurullo, F ;
Mezzetti, A .
CIRCULATION, 2003, 107 (11) :1479-1485
[9]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[10]   Characterization of endothelial factors involved in the vasodilatory effect of simvastatin in aorta and small mesenteric artery of the rat [J].
de Sotomayor, MA ;
Herrera, MD ;
Marhuenda, E ;
Andriantsitohaina, R .
BRITISH JOURNAL OF PHARMACOLOGY, 2000, 131 (06) :1179-1187